Dr. Christian Schmees - NMI.de

Arbeitsgebiete

Patientenabgeleitete ex vivo Tumormodelle und deren Einsatz zur präklinischen Effizienztestung von Wirkstoffen, Tumor-Immunzell Interaktionen mit Fokus auf T Lymphozyten und Makrophagen, Optogenetische Modulation von Zell-Zell-Kommunikation und zellulärer Signalübertragung, CRISPR-basierte Genom-Editierung zur Target Validierung und zum Engineering zellulärer Modelle

Werdegang mit den wichtigsten Stationen

2014 - heute Leiter Tumorbiologie, NMI

2011 - 2014 Wissenschaftler, Arbeitsgruppe Tumorbiologie, NMI

2010 - 2011 Wissenschaftler, Abteilung für Systemische Zellbiologie (Prof. Philippe Bastiaens),
Max-Planck-Institute für Molekulare Physiologie, Dortmund

2006 – 2010 PostDoc, Ludwig Institute for Cancer Research (LICR; Prof. Carl-Henrik Heldin) Uppsala, Schweden (Stipendien von LICR und DFG “Investigation of Differences in Regulation of intracellular trafficking of PDGF α- and β-receptors”)

2002 – 2006 Promotion (Dr. rer nat.), Klinik für Innere Medizin II, Technische Universität München

1996 – 2002 Biochemie Studium, Universitäten Halle-Wittenberg und Tübingen

Dr. Christian Schmees

Diplom-Biochemiker

T +49 (0)7121 51530-881

E christian.schmees@nmi.de

Projekte

Publikationen

A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies

Gürgen, D., Becker, M., Dahlmann, M., Flechsig, S., Schäffeler, E., Büttner, F., Schmees, C., Bohnert, R., Bedke, J., Schwab, M., Wendler, J., Schostak, M., Jandrig, B., Walther, W., Hoffmann, J.

https://doi.org/10.3389/fonc.2022.889789
A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer

Anderle, N., Koch, A., Gierke, B., Keller, A. L., Staebler, A., Hartkopf, A., Brucker, S. Y., Pawlak, M., Schenke-Layland, K., & Schmees, C.

Cancers, 14(12), 2895. https://doi.org/10.3390/cancers14122895
Continous, non-invasive monitoring of oxygen consumption in a parallelized microfluidic in vitro system provides novel insight into the response to nutrients and drugs of primary human hepatocytes

Busche N, Rabl D, Fischer J, Schmees C, Mayr T, Gebhardt R, Stelzle M

DOI: https://doi.org/10.17179/excli2021-4351
Advancement of precision oncology by integration of highly sensitive protein profiling technologies and patient-derived cell models for functional efficacy testing

Pawlak, M., Templin, M., & Schmees, C.

Immuno-Oncology Insights, 2(4), 171–185. https://doi.org/10.18609/ioi.2021.013
Parallelizable Microfluidic Platform to Model and Assess In Vitro Cellular Barriers: Technology and Application to Study the Interaction of 3D Tumor Spheroids with Cellular Barriers

Nair A L , Mesch L, Schulz I, Becker H , Raible J, Kiessling H, Werner S, Rothbauer U , Schmees C, Busche M, Trennheuser S, Fricker G and Stelzle M

Biosensors 2021, 11, 314. https://doi.org/10.3390/bios11090314
Argyrin F Treatment-Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma

Walter B, Canjuga D, Yüz S, Ghosh M, Bozko P, Przystal J, Govindarajan P, Anderle N, Keller AL, Tatagiba M, Schenke-Layland K, Rammensee HG, Stevanovic S, Malek N P, Schmees C, and TabatabaiG

DOI: 10.1002/adtp.202100078
Generation and characterization of the human induced pluripotent stem cell line NMIi010-A from peripheral blood mononuclear cells of a healthy 49–year old male individual

Keller AK, Binner A, Breitmeyer R, Vogel S, Anderle N, Rothbauer U, Schenke-Layland K, Schmees C

Stem Cell Research Volume 54, July 2021, 102427, https://doi.org/10.1016/j.scr.2021.102427
Generation and characterization of the human induced pluripotent stem cell line NMIi010-A from peripheral blood mononuclear cells of a healthy 49–year old male individual

Keller AL, Binner A, Breitmeyer R, Vogel S, Anderle N, Rothbauer U, Schenke-Layland K, Schmees C

tem Cell Res. 2021 Jul;54:102427. doi: 10.1016/j.scr.2021.102427. Epub 2021 Jun 11. PMID: 34139596.
Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma

Przystal JM, Becker H, Canjuga C, Tsiami F, Anderle N, Keller A, Pohl A, Ries CH, Schmittnaegel M, Korinetska N, Koch M, Schittenhelm J, Tatagiba M, Schmees C, Beck SC, Tabatabai G

Cancers 2021, 13(10), 2400; https://doi.org/10.3390/cancers13102400
HepaChip-MP – a twenty-four chamber microplate for a continuously perfused liver coculture model

Busche M, Tomilova O, Schütte J, Werner S, Beer M, Groll N, Hagmeyer B, Pawlak M, Jones P D, Schmees C, Becker H, Schnabel J, Gall K, Hemmler R, Matz-Soja M, Damm G, Beuck S, Klaassen T, Moer J, Ullrich A, Runge D, Schenke-Layland K, Gebhardt R und Stelzle M

Lab on a Chip, DOI: 10.1039/d0lc00357c
A peptide tag-specific nanobody enables high-quality labeling for dSTORM imaging

Virant D, Traenkle B, Maier J, Kaiser PD, Bodenhöfer M, Schmees C, Vojnovic I, Pisak-Lukáts B, Endesfelder U, Rothbauer U

Nature Communications. 2018 Mar;9:930. DOI:10.1038/s41467-018-03191-2
Functional protein and pathway profiling of patient-derived tumor models for drug testing and precision medicine applications using Reverse Phase Protein Arrays (RPPA)

Gierke B, Bodenhofer M, Schmees C, Pawlak M

European Journal of Cancer. 2018 November 13-16; 103S1 (e21–e1489):e109
A novel microfluidic 3D platform for culturing pancreatic ductal adenocarcinoma cells: comparison with in vitro cultures and in vivo xenografts

Beer M, Kuppalu N, Stefanini M, Becker H, Schulz I, Manoli S, Schuette J, Schmees C, Casazza A, Stelzle M, Arcangeli A

Sci Rep. 2017 Apr 25;7(1):1325. doi: 10.1038/s41598-017-01256-8.
Role of BCL9L in transforming growth factor-beta (TGF-beta)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer

Sannino G, Armbruster N, Bodenhofer M, Haerle U, Behrens D, Buchholz M, Rothbauer U, Sipos B, Schmees C

Oncotarget. 2016 Oct 4; 7:73725-73738. doi: 10.18632/oncotarget.12455.
Live imaging of endogenous protein dynamics in zebrafish using chromobodies.

Panza P, Maier J, Schmees C, Rothbauer U, Söllner C.

Development. 2015 May 15;142(10):1879-84. doi: 10.1242/dev.118943.
Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells

Kaistha BP, Honstein T, Muller V, Bielak S, Sauer M, Kreider R, Fassan M, Scarpa A, Schmees C, Volkmer H, Gress TM, Buchholz, M

Br J Cancer. 2014 Oct 28;111(9):1780-7. doi: 10.1038/bjc.2014.460. Epub 2014 Aug 19.
Macropinocytosis of the PDGF β-receptor promotes fibroblast transformation by H-RasG12V.

Schmees C, Villaseñor R, Zheng W, Ma H, Zerial M, Heldin CH, Hellberg C

Mol Biol Cell. 2012 Jul 1; 23(13): 2571–2582. doi: 10.1091/mbc.E11-04-0317

Zurück